Related Experiment Video
Updated: Oct 25, 2026

CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable Diagnostics
Published on: December 8, 2023
Cell-Surface-to-Solution Signal Transduction via a CRISPR/Cas12a-Based Dual-Target Aptamer Sensor for Detecting
Shun-Li Wu1,2, Jia-Yi Shi1,2, Yan Tan3
1State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, Nankai University, Tianjin300071, P. R. China.
Abstract:
Urothelial carcinoma (UC) is a common malignancy of the genitourinary system with high recurrence rates, requiring non-invasive postoperative monitoring. Direct detection of exfoliated UC cells in urine can provide tumor-origin evidence but remains challenging because of low target-cell abundance, complex urine interference, and subjective cytological interpretation. Herein, we developed a CRISPR/Cas12a-based dual-target aptamer sensor for sensitive and specific detection of exfoliated UC cells in urine. The sensing system spatially couples CKAP4-mediated magnetic capture with PD-L1-dependent retention of a Cas12a activator on the same captured cell. Magnetic washing removes unbound activator probes, whereas the cell-retained activator subsequently initiates Cas12a trans-cleavage in the solution-phase reaction. This capture-retain-activate architecture provides an AND-gate-like route for converting spatially coupled cell-surface recognition events into an amplified fluorescence output. The sensor achieved a detection limit of 12 cells per assay and showed good selectivity against interfering cells. A pilot clinical evaluation using 32 urine samples distinguished UC patients from non-UC individuals with an area under the receiver operating characteristic curve (AUC) of 0.996. This work provides a capture-retain-activate strategy for the non-invasive analysis of intact exfoliated UC cells and illustrates a potential design route for coupling cell-surface recognition with solution-phase CRISPR/Cas12a signal amplification.

